Dachaigh › Neuroblastoma › New York
Sgrùdaidhean clionaigeach Neuroblastoma ann an New York
Tha 13 sgrùdaidhean airson Neuroblastoma a’ lorg phàirtichean aig làraichean ann an New York.
Bailtean ann an New York
Teacsa sgrùdaidh oifigeil (Beurla)
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- Memorial Sloan Kettering Cancer Center, New York
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT00588068Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- NYU Langone Hospital - Long Island, Mineola
- agus 7 a bharrachd
A’ fastadhÌre 3
Suas gu aois 30 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06172296A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- Memorial Sloan Kettering Cancer Center, New York
A’ fastadhÌre 2Fàilte do shaor-thoilich fhallain
Gach aois · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT04936529Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
- New York Medical College ( Site 1023), Valhalla
A’ fastadhÌre 1/2
6 Months – 25 Years · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT06395103N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- Memorial Sloan Kettering Cancer Center, New York
A’ fastadhÌre 2
18 Months – 19 Years · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT06528496Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- agus 8 a bharrachd
A’ fastadhÌre 3
365 Days – 30 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A’ fastadhÌre 1/2
12 Months – 30 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Memorial Sloan Kettering Kids, New York
A’ fastadhÌre 1/2
Aoisean 2 gu 21 · Gach gnè · Air ùrachadh 11 Lùna 2026 · NCT05642455A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
- Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- agus 1 a bharrachd
A’ fastadhÌre 2
Gach aois · Gach gnè · Air ùrachadh 28 Iuch 2026 · NCT06057948Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- Memorial Sloan Kettering Cancer Center, New York
A’ fastadhÌre 2
Aoisean 1 agus nas sine · Gach gnè · Air ùrachadh 29 Cèit 2026 · NCT00107289Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
- New York Medical College, Valhalla
A’ fastadhÌre 1
Aoisean 1 gu 30 · Gach gnè · Air ùrachadh 15 Gibl 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- Albert Einstein College of Medicine, Children's Hospital at Montefiore, The Bronx
- New York Medical Center/ Maria Fareri Children's Hospital, Valhalla
A’ fastadhÌre 2
Aoisean 1 gu 50 · Gach gnè · Air ùrachadh 13 Màrt 2026 · NCT01804634A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's Hospital at Montefiore, The Bronx
A’ fastadhÌre 2
18 Months – 40 Years · Gach gnè · Air ùrachadh 12 Lùna 2025 · NCT05135975Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.